Phase II trial of carboplatin/paclitaxel and cetuximab, followed by carboplatin/paclitaxel/cetuximab and erlotinib, in metastatic or recurrent squamous cell carcinoma of the head and neck.

被引：2
|
作者：
Bhatia, Aarti K.
Mehra, Ranee
Khan, Saad A.
Egleston, Brian L.
Alpaugh, R. Katherine
Lango, Miriam
Ridge, John A.
Burtness, Barbara
机构：
[1] Yale Sch Med, New Haven, CT USA
[2] Yale Canc Ctr, New Haven, CT USA
[3] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[4] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[5] Yale Univ, Yale Canc Ctr, New Haven, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.6027
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6027
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Predictors of Outcome With Cetuximab and Paclitaxel for Head and Neck Squamous Cell Carcinoma
    Ferreira, Bruna Pellini
    Redman, Mary
    Baker, Kelsey K.
    Martins, Renato
    Eaton, Keith D.
    Chow, Laura Quan Man
    Baik, Christina S.
    Goulart, Bernardo
    Lee, Sylvia Mina
    Santana-Davila, Rafael
    Rodriguez, Cristina P.
    LARYNGOSCOPE, 2017, 127 (07): : 1583 - 1588
  • [32] A comparison of weekly paclitaxel and cetuximab with the EXTREME regimen in the treatment of recurrent/metastatic squamous cell head and neck carcinoma
    Nakano, Kenji
    Marshall, Shoko
    Taira, Shinichiro
    Sato, Yukiko
    Tomomatsu, Junichi
    Sasaki, Toru
    Shimbashi, Wataru
    Fukushima, Hirofumi
    Yonekawa, Hiroyuki
    Mitani, Hiroki
    Kawabata, Kazuyoshi
    Takahashi, Shunji
    ORAL ONCOLOGY, 2017, 73 : 21 - 26
  • [33] Weekly paclitaxel, carboplatin and cetuximab (PCC) combination followed by nivolumab in platinum-sensitive recurrent and/or metastatic squamous cell carcinoma of head and neck: A double institution retrospective analysis from India
    Agarwala, V.
    Chandrakanth, M. V.
    Mondal, P. K.
    Chanana, R.
    ANNALS OF ONCOLOGY, 2020, 31 : S1350 - S1350
  • [34] Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck
    Argiris, A.
    Kotsakis, A. P.
    Hoang, T.
    Worden, F. P.
    Savvides, P.
    Gibson, M. K.
    Gyanchandani, R.
    Blumenschein, G. R., Jr.
    Chen, H. X.
    Grandis, J. R.
    Harari, P. M.
    Kies, M. S.
    Kim, S.
    ANNALS OF ONCOLOGY, 2013, 24 (01) : 220 - 225
  • [35] Weekly vs. 3-weekly paclitaxel, carboplatin, and cetuximab (PCC) in recurrent/metastatic head and neck cancer
    Geraghty, Leeann
    Schultz, Thomas E.
    Hoffman, Sarah E.
    Porter, Kyle
    Issa, Majd
    Karivedu, Vidhya
    Bonomi, Marcelo
    MOLECULAR AND CLINICAL ONCOLOGY, 2021, 15 (05)
  • [36] Quality of life of elderly patients receiving weekly carboplatin and paclitaxel chemotherapy plus cetuximab first line for metastatic squamous cell carcinoma of the head and neck
    Lugini, A.
    Rossi, R.
    Pace, R.
    Rauco, A.
    Santarelli, M.
    Capparella, V.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S752 - S752
  • [37] A phase II study of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic or recurrent squamous cell cancer of the head and neck (SCCHN).
    Sabichi, A. L.
    Kies, M. S.
    Glisson, B. S.
    Lu, C.
    Ginsberg, L. E.
    Bartos, C. I.
    Feng, L.
    Tran, H. T.
    Lippman, S. M.
    Blumenschein, G. R., Jr.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [38] Efficacy and tolerability of a low dose weekly paclitaxel, carboplatin and cetuximab (PCC) regimen for metastatic or unresectable head and neck squamous cell carcinomas
    Locke, Margaret
    Kohn, Nina
    Seetharamu, Nagashree
    CLINICAL OTOLARYNGOLOGY, 2023, 48 (06) : 915 - 919
  • [39] Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck
    Hitt, R.
    Irigoyen, A.
    Cortes-Funes, H.
    Grau, J. J.
    Garcia-Saenz, J. A.
    Cruz-Hernandez, J. J.
    ANNALS OF ONCOLOGY, 2012, 23 (04) : 1016 - 1022
  • [40] WEEKLY REGIMEN OF PACLITAXEL-CARBOPLATIN-CETUXIMAB AS FIRST-LINE CHEMOTHERAPY IN PATIENTS WITH PLATINUM-RESISTANT RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF HEAD AND NECK (SSCHN): RESULTS OF A PHASE II STUDY
    Rozzi, A.
    Lenci, G.
    Corona, M.
    Nardoni, C.
    Restuccia, M. R.
    Falbo, T.
    Nappa, M.
    Costa, A. M.
    Spigone, B.
    Lanzetta, G.
    ANNALS OF ONCOLOGY, 2010, 21 : 323 - 323
12345